RxSight Inc
$14.5M 7,552 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
NovApproach Spine, LLC
NovApproach Spine, LLC reported $14,490,691.67 across General Payments, Research, and Ownership to 178 physicians and teaching hospitals across 211 transactions.
- $14.5M
- All-tracks total
- 211
- Transactions
- 178
- Recipients
- +$50.8K
- General Payments vs PY2023
NovApproach Spine, LLC reported $14,490,691.67 across all CMS Open Payments tracks (General + Research + Ownership) to 178 physicians and teaching hospitals in Program Year 2024 - ranking #131 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $88,354.42, averaging $81.4K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer novapproach-spine-llc NovApproach Spine, LLC
$14.5M · #131/1,925 · 0.1% industry · PY2024
- TOT $14.5M
- RANK #131
- SHARE 0.1%
- TXN 211
- RCP 178
- CAT 3
- GEN $88.4K
- ΔGEN +$50.8K
- TOP1 50.4%
- PY 2024
Volume peers
Nearest volume peer: RxSight Inc ($14.5M)
NovApproach Spine, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
NovApproach Spine, LLC's CMS-reported General Payments increased by $50.8K (+135.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NOVAPPROACH SPINE, LLCPY2023: NOVAPPROACH SPINE, LLCPY2024: NovApproach Spine, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $37,581.74
- PY2024
- $88,354.42
What the Data Shows for NovApproach Spine, LLC
Averaging $68.7K per transaction and $81.4K per recipient, NovApproach Spine, LLC's Program Year 2024 total comes to $14,490,691.67 across 211 transactions and 178 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #131 of 1,925 companies, representing 0.1% of all industry payments reported nationwide for the year.
The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $75.1K, accounting for 85.0% of this company's General Payments and 73 transactions.
General Payment Breakdown by Type
"Consulting Fee" leads NovApproach Spine, LLC's 3-category general-payment breakdown at $75.1K, 85.0% of the reported total.
How NovApproach Spine, LLC divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $75.1K | 73 | 85.0% |
| Travel and Lodging | $10.8K | 43 | 12.2% |
| Food and Beverage | $2.5K | 62 | 2.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $74,395.24 (84.2%) of $88,354.42 in this company's General Payments records across 27 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for NovApproach Spine, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Michael Macmillan
$44,574.25 across 101 reported transactions
- 2
John Liu
$9,625.00 across 11 reported transactions
- 3
Payam Moazzaz
$8,214.25 across 12 reported transactions
- 4
Hunaldo Villalobos
$6,161.85 across 2 reported transactions
- 5
Thomas Terramani
$5,819.89 across 7 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as NovApproach Spine, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about NovApproach Spine, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with NovApproach Spine, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Otsuka America Pharmaceutical, Inc.
$14.5M 186,436 recipients
Compare payment profiles
Swedish Orphan Biovitrum Ab
$14.7M 55 recipients
Compare payment profiles
Otsuka Pharmaceutical Development & Commercialization, Inc.
$14.8M 4,515 recipients
Compare payment profiles
Argenx US, Inc.
$14.1M 19,529 recipients
Compare payment profiles
Roche Diagnostics Operations, Inc.
$14.9M 0 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.